RxDoctor Payments Data

Ebonee Davis, MD

Internal Medicine · South Bend, INNPI 1295725646

Payments from drug & device makers

$523in general payments, 2019–2025

Across 29 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$154
  • Novartis$113
  • Lilly USA, LLC$94
  • Amgen$60
  • Insulet Corporation$29
  • Abbott$21
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$523 in reported general payments places this provider in the 65th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$137,321
Medicare patients
296
Services billed
3,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide196$240,210
EliquisApixaban160$150,012
JanuviaSitagliptin Phosphate104$121,061
OzempicSemaglutide90$113,123
TrulicityDulaglutide73$99,273
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$64,592
XareltoRivaroxaban47$47,883
Janumet XrSitagliptin Phos/Metformin Hcl44$46,434
Breo ElliptaFluticasone/Vilanterol66$41,466
JardianceEmpagliflozin28$27,555
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$24,517
Lantus SolostarInsulin Glargine,hum.Rec.Anlog107$21,311
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$15,855
MyrbetriqMirabegron18$14,589
Tresiba Flextouch U-100Insulin Degludec27$14,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$94$339,483269 claims
Novo NordiskOzempic$154$113,12390 claims
NovartisEntresto$113$13,01412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →